NFKB1 and Hepatic fibrosis: These results clearly indicate that the systemic administration of Exo-SrIκB effectively suppressed the translocation of NF-κB to the nucleus, leading to pronounced anti-inflammatory and antifibrotic effects in the BDL-induced liver fibrosis model.